PART I Item 1. B usiness. Overview We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need. Our mos...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-132085 | EDGAR | 110K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043486 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0000950170-24-028941 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-265757 | EDGAR | 78K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108427 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-068536 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125943 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095057 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056247 | EDGAR | — |
| 2023-12-11 | 2023-09-30 | 0000950170-23-069192 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-131792 | EDGAR | 2K words |
| 2026-02-05 | 0001193125-26-039425 | EDGAR | — |
| 2026-01-27 | 0001193125-26-023339 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010091 | EDGAR | — |
| 2025-11-05 | 0001193125-25-265755 | EDGAR | — |
| 2025-10-17 | 0001193125-25-242652 | EDGAR | — |
| 2025-10-07 | 0001193125-25-232514 | EDGAR | — |
| 2025-08-14 | 0000950170-25-108426 | EDGAR | — |
| 2025-06-30 | 0000950170-25-091671 | EDGAR | — |
| 2025-05-27 | 0000950170-25-077377 | EDGAR | — |
55 total filings indexed. 35 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001907108 |
| Ticker | LXEO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.lexeotx.com |
| Listed | 2023-11-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report